174 related articles for article (PubMed ID: 32878812)
1. Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/lymphoma.
Jo T; Matsuzaka K; Shioya H; Tominaga H; Sakai T; Kaneko Y; Hayashi S; Matsuo M; Taguchi J; Abe K; Shigematsu K; Kubota-Koketsu R
Anticancer Res; 2020 Sep; 40(9):5237-5243. PubMed ID: 32878812
[TBL] [Abstract][Full Text] [Related]
2. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Ishida T; Jo T; Takemoto S; Suzushima H; Uozumi K; Yamamoto K; Uike N; Saburi Y; Nosaka K; Utsunomiya A; Tobinai K; Fujiwara H; Ishitsuka K; Yoshida S; Taira N; Moriuchi Y; Imada K; Miyamoto T; Akinaga S; Tomonaga M; Ueda R
Br J Haematol; 2015 Jun; 169(5):672-82. PubMed ID: 25733162
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
Roswarski J; Roschewski M; Lucas A; Melani C; Pittaluga S; Jaffe ES; Steinberg SM; Waldmann TA; Wilson WH
Leuk Lymphoma; 2018 Jun; 59(6):1466-1469. PubMed ID: 29032710
[No Abstract] [Full Text] [Related]
4. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
6. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
8. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2001 Mar; 1(4):285-92. PubMed ID: 11707843
[TBL] [Abstract][Full Text] [Related]
9. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of the Modified EPOCH Regimen (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Adult T-cell Leukemia/Lymphoma: A Multicenter Retrospective Study.
Tsukamoto Y; Kiyasu J; Choi I; Kozuru M; Uike N; Utsunomiya H; Hirata A; Fujioka E; Ohno H; Nakashima E; Nakashima Y; Miyashita K; Tachikawa Y; Narazaki T; Tsuda M; Haji S; Takamatsu A; Tanaka E; Goto T; Takatsuki H; Oyama M; Muta H; Yagi Y; Ikeda M; Matsushima T; Yufu Y; Suehiro Y
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e445-e453. PubMed ID: 32312633
[TBL] [Abstract][Full Text] [Related]
11. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
12. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K; Utsunomiya A; Fukuda H; Shibata T; Fukushima T; Takatsuka Y; Ikeda S; Masuda M; Nagoshi H; Ueda R; Tamura K; Sano M; Momita S; Yamaguchi K; Kawano F; Hanada S; Tobinai K; Shimoyama M; Hotta T; Tomonaga M;
J Clin Oncol; 2007 Dec; 25(34):5458-64. PubMed ID: 17968021
[TBL] [Abstract][Full Text] [Related]
13. Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States.
Roe C; Komrokji R; Zhang L; Price S; Sokol L
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S191-4. PubMed ID: 27521318
[TBL] [Abstract][Full Text] [Related]
14. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience.
Makiyama J; Imaizumi Y; Tsushima H; Taniguchi H; Moriwaki Y; Sawayama Y; Imanishi D; Taguchi J; Hata T; Tsukasaki K; Miyazaki Y
Int J Hematol; 2014 Nov; 100(5):464-72. PubMed ID: 25209605
[TBL] [Abstract][Full Text] [Related]
16. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
[TBL] [Abstract][Full Text] [Related]
17. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
Alduaij A; Butera JN; Treaba D; Castillo J
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
[TBL] [Abstract][Full Text] [Related]
18. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
19. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma.
Ratner L; Rauch D; Abel H; Caruso B; Noy A; Barta SK; Parekh S; Ramos JC; Ambinder R; Phillips A; Harding J; Baydoun HH; Cheng X; Jacobson S
Blood Cancer J; 2016 Mar; 6(3):e408. PubMed ID: 27015285
[No Abstract] [Full Text] [Related]
20. A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.
Sekiguchi Y; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Kinoshita A; Suga Y; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6278-90. PubMed ID: 25337281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
